Literature DB >> 8151460

Neurofibromatosis type 1: the cognitive phenotype.

K J Hofman1, E L Harris, R N Bryan, M B Denckla.   

Abstract

Visuospatial deficits have been reported in patients with neurofibromatosis type 1 (NF 1), although detailed observations regarding academic achievement are conflicting. Using neurocognitive testing and magnetic resonance imaging, we studied 12 families, each comprising one child with NF 1, an unaffected sibling of the same age range (6 to 16 years), and both biologic parents. The Full Scale IQ ranged from 70 to 130 among children with NF 1 and from 99 to 139 among unaffected siblings. A significant (p < 0.01) pairwise difference was found between each child with NF 1 and sibling on the Full Scale IQ and the Verbal IQ. On a single visuospatial test, Judgement of Line Orientation, children with NF 1 did significantly worse than siblings (p < 0.01). Children with NF 1 had significant learning disabilities in written language and reading (p < 0.05) and in neuromotor dysfunction (p < 0.005) compared with siblings. A significant correlation was found between the pairwise lowering of the Full Scale IQ and Judgment of Line Orientation scores in children with NF 1 and the number of locations in which, on magnetic resonance imaging, T2-weighted hyperintensities were seen (Full Scale IQ: p < 0.0003; Judgment of Line Orientation score: p < 0.02). We conclude that NF 1 is associated with a significantly lower Full Scale IQ, multifocal cognitive deficits (Verbal IQ, Judgment of Line Orientation score), reading disability, and neuromotor deficit. Pairwise cognitive differences correlated with the number of brain lesions on magnetic resonance imaging.

Entities:  

Mesh:

Year:  1994        PMID: 8151460     DOI: 10.1016/s0022-3476(05)83163-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  26 in total

1.  A child with axillary freckling and café au lait spots.

Authors:  Stephen Wainer
Journal:  CMAJ       Date:  2002-08-06       Impact factor: 8.262

Review 2.  Molecular and cellular mechanisms of learning disabilities: a focus on NF1.

Authors:  C Shilyansky; Y S Lee; A J Silva
Journal:  Annu Rev Neurosci       Date:  2010       Impact factor: 12.449

Review 3.  Understanding intellectual disability through RASopathies.

Authors:  Alvaro San Martín; Mario Rafael Pagani
Journal:  J Physiol Paris       Date:  2014-05-21

4.  Brief report: the association of neurofibromatosis type 1 and autism.

Authors:  P G Williams; J H Hersh
Journal:  J Autism Dev Disord       Date:  1998-12

5.  Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials.

Authors:  Jonathan M Payne; Belinda Barton; E Arthur Shores; Kathryn N North
Journal:  J Neurol       Date:  2012-08-09       Impact factor: 4.849

6.  Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life.

Authors:  Pamela L Wolters; Katherine M Burns; Staci Martin; Andrea Baldwin; Eva Dombi; Mary Anne Toledo-Tamula; William N Dudley; Andrea Gillespie; Brigitte C Widemann
Journal:  Am J Med Genet A       Date:  2015-05-14       Impact factor: 2.802

7.  Cognitive profile of children with neurofibromatosis and reading disabilities.

Authors:  Laurie E Cutting; Terry M Levine
Journal:  Child Neuropsychol       Date:  2010       Impact factor: 2.500

8.  Age-related findings on MRI in neurofibromatosis type 1.

Authors:  Deepak S Gill; Shelley L Hyman; Adam Steinberg; Kathryn N North
Journal:  Pediatr Radiol       Date:  2006-08-16

9.  Visuospatial processing in children with neurofibromatosis type 1.

Authors:  Amy M Clements-Stephens; Sheryl L Rimrodt; Pooja Gaur; Laurie E Cutting
Journal:  Neuropsychologia       Date:  2007-10-02       Impact factor: 3.139

Review 10.  Update on the management of familial central nervous system tumor syndromes.

Authors:  Andreas F Hottinger; Yasmin Khakoo
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.